The guidelines by ADA suggest that in patients with established cardiovascular disease, kidney disease, or heart failure, sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 RA should be considered regardless of glycated hemoglobin (HbA1c) levels. This evidence concerns the gene GCG and cardiovascular disorder.